While individual components of the therapy, such as ARNIs and SGLT2 inhibitors, have shown efficacy in reducing morbidity and mortality by improving hemodynamics and reducing neuroendocrine activation, their combined impact on the complex neuroendocrine feedback loop in heart failure patients has not been adequately addressed. This evidence concerns the gene SLC5A2 and heart failure.